Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis

Maximilian Stahl, Jan Phillip Bewersdorf, Smith Giri, Rong Wang, and Amer M. Zeidan

Disclosures: A.M.Z. received research funding (institutional) from Celgene, Acceleron, Abbvie, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Ariad, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Seattle Genetics, BeyondSpring, and Takeda. None of these relationships were related to the development of this manuscript. All other authors report no relevant disclosures/competing interests

Contributions: MS designed the study, performed data analysis, interpreted the data and wrote the manuscript. JPB performed data analysis, interpreted the data, and wrote the manuscript. SG and RW analyzed and interpreted the data, and critically reviewed the manuscript. AMZ interpreted the data and critically reviewed and contributed to the manuscript significantly. All authors approved the final manuscript for submission.